Claudia Altamura, MD, PhD, University of Rome, Rome, Italy, discusses the burden chronic migraine places on patients and their families. The use of monoclonal antibodies has revolutionized migraine treatment by offering rapid and effective relief, in many cases decreasing occurrence from chronic to episodic. It’s increasingly important to have personalized treatment options, accommodating patient preferences and treating quickly. This interview took place at the European Academy of Neurology (EAN) 2023 Congress in Budapest, Hungary.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.